ABSTRACT

Introduction While the need for palliative care for people living with dementia has widely been recognised, they continue to be a disadvantaged group when it comes to timely initiation, and controversies remain regarding appropriate timing, or what elements constitute high quality palliative care early in the disease trajectory. To date, no literature review has summarised this debate or offered insights. The aim of this scoping review is to provide a general overview of research regarding palliative care in mild or moderate dementia, to identify existing controversies, and to examine what are key components of palliative care in dementia, specifically when initiated earlier in the disease trajectory.

Methods and analysis Consistent with recent guidelines and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews, we carried out a search for academic literature in PubMed, CINAHL, EMBASE, Cochrane Library, PsycINFO, Web of Science; on 5 November 2019 and an updated search on 2 February 2021. We will include studies with different study designs published in English over the last decade that focused on palliative care in early stages of dementia. We will include models targeting at least one outcome domain of palliative care (physical, psychological, social or spiritual) and advance care planning, and will exclude hospice models with limited prognosis similar to the requirements in the USA. We will report study characteristics and quality. We aim to apply narrative synthesis techniques to develop a theoretical model of how, for whom and why palliative care can be relevant in early stages of dementia, and what are facilitators and barriers. We anticipate to also describe if and how the concept of (early) palliative care changed across time and studies.

Ethics and dissemination No ethical review required. Results will identify research gaps and lay out basic principles for conceptualising palliative care in early stages of dementia.

BACKGROUND

Dementia is characterised by a protracted course with progressive but insidious development of cognitive and physical disability. It has become an increasingly prevalent cause of death.1 By 2050, over 40% of adults aged 65 and older will die with or from dementia.13 Although there is widespread recognition that palliative care has much to offer people living with dementia and their loved ones4,5 from the time of diagnosis across the disease course,6,7 people with dementia are consistently shown to be a disadvantaged group when it comes to timely and high-quality palliative care.

Palliative care focuses on improving the quality of life of individuals and their families facing problems associated with serious illness through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual.8-10 However, despite dementia being associated with decreased life expectancy, many do not perceive it to be life-limiting or terminal at time of diagnosis or earlier in the course of disease.2 Lack of access to palliative care results in a large amount of unmet needs, a high burden of pain, other sources of distress, and frequent burdensome
hospitalisations and invasive procedures—that neither improve the length nor the quality of life.\textsuperscript{15,11} Time trend analysis of population-based data in Belgium shows that over the years, the timing of initiating specialist palliative care services (such as palliative care home team, palliative care unit, palliative care team in nursing home or mobile palliative care support hospital-based team) in dementia continues to occur very close to death.\textsuperscript{12} This is consistent with other international literature showing that palliative care is generally initiated late for all conditions; especially in dementia, at a median (P25–75) up to only 14 days (7–30) before death.\textsuperscript{13,14} In the USA, although there has been a large increase in access to hospice for people with dementia to the point that almost half of all hospice recipients annually have a primary or comorbid diagnosis of dementia,\textsuperscript{3,15} people with dementia still only have a median length of stay in hospice of only 17 days, and many exceed the 6-month time limit, with live discharge.\textsuperscript{17} In addition, almost half of national dementia plans around the world lack any reference to end-of-life care or palliative care.\textsuperscript{18}

There has been much debate about palliative care in the early stages of the dementia trajectory,\textsuperscript{19–21} with a variety of opinions between healthcare professionals.\textsuperscript{19,22} There are controversies regarding the timing and appropriateness of adopting a palliative care approach, and what it should constitute.\textsuperscript{19–21}

Professionals across Europe and internationally have different opinions regarding the time point to when to consider a person with dementia in need of palliative care.\textsuperscript{19,22–24} The spectrum of experience in dementia is argued to be both vast and profound—changes may be relatively easy to manage or extremely complex,\textsuperscript{2} which can be compounded by an unpredictable disease course and the potential for people to have a prolonged experience of its most advanced and debilitating stage.\textsuperscript{25,26} Despite the call for research into palliative care across different stages of dementia,\textsuperscript{27} it has been argued that the appropriateness of palliative care initiation depending on stages of dementia might be challenging—people with dementia in earlier stages may be in the terminal phase; patients may survive to the last phase of dementia with severe physical and cognitive impairment\textsuperscript{1} but may also die earlier from comorbid conditions for example. While some argue a more advanced stage of dementia is the best time to start palliative care,\textsuperscript{19} others argue that waiting until the advanced stage of the illness might reduce opportunities for improving quality of life for the patient and caregiver earlier in the disease course,\textsuperscript{28} including the option to still have meaningful conversations. Anticipating the progression of the disease by initiating advance care planning when the patient can still be actively involved and when patient preferences, values, needs and beliefs can be elicited, argues for earlier palliative care involvement\textsuperscript{2} or social and spiritual support.\textsuperscript{3}

Then there are those arguing palliative care initiation should not depend on prognosis or age, rather on care needs.\textsuperscript{29,30}

Appropriateness of palliative care early on is sometimes questioned.\textsuperscript{23} A recent study for example reports that specialist palliative care services in dementia were not initiated because of physicians’ consideration of palliative care ‘as not being meaningful’ in dementia.\textsuperscript{32} Earlier initiation of palliative care is sometimes perceived to add to distress, or perceived loss of hope for the person with the condition and their family members.\textsuperscript{20,32} However, there is growing interdisciplinary consensus that the concept of a relatively short period of decline towards death is uncommon in persons with dementia and an increasing number of older people with dementia will experience prolonged periods, possibly many years (eg, young-onset dementia\textsuperscript{33}), of profound disability where any exacerbation of their condition could potentially be fatal and where palliative care is extremely valuable.\textsuperscript{34}

It is still unclear how to shape palliative care in dementia in practice and what effective care would look like at different points in the dementia trajectory, especially early on.\textsuperscript{25} We currently lack insight into what types of services should/can be offered at an earlier stage, which term is preferred (notion of ‘supportive care’ has been proposed\textsuperscript{33}), and how this all relates to what are key components palliative care early in the disease course,\textsuperscript{23} beyond proactive (care) planning.\textsuperscript{8,19,20,22} Nor has there been an exploration of how these controversies vary between countries and healthcare systems, which may have different approaches to dementia palliative care.\textsuperscript{35–38}

Hence, while the general zeitgeist seems to call on timely and early initiation of palliative care in dementia,\textsuperscript{3,39} there is no literature review that to date has summarised the scientific debate or offered insights on what combination of elements constitutes high-quality timely palliative care. While multiple reviews on dementia and palliative care have been published,\textsuperscript{27,40,41} these have focused on palliative care at the end-of-life, terminal or advanced stages of the disease\textsuperscript{42} or were limited to specific settings (eg, long-term care facilities or at home).\textsuperscript{44} Other reviews specifically aimed to evaluate effects of palliative care,\textsuperscript{45} barriers and facilitators for its optimal implementation, or how people experience palliative care by various perspectives.\textsuperscript{46–47}

**General aim and research questions**

We aim to conduct a scoping review of the literature in order to systematically map the research done in palliative care early in the disease trajectory of people living with mild and moderate dementia, as well as to identify any existing gaps in knowledge, current scientific debates and conceptualisations. Early palliative care in this study is defined as ‘in the early stages of the disease trajectory of dementia’, starting from diagnosis. Hence, not focused on people living with advanced, end-stage, terminal stages of dementia. Palliative care in this review is conceptualised as defined by the WHO,\textsuperscript{3} that is related to one, more or all of its domains (physical, social, psychological, spiritual) and can be provided by any type of generalist or specialist (palliative care) healthcare provider. Generalist
palliative care most often being provided by generalist healthcare professionals and/or providers not specialised in palliative care. Specialist palliative care intended to be provided by professionals (and the services they compose) that work solely in the field of palliative care and whose main activity is devoted to dealing with complex problems requiring specialist palliative care skills and competencies.44 48

Guiding research questions—among others that we may derive from the review data—include:
1. How is ‘early’, ‘timely’, ‘earlier’ palliative care defined, in relation to dementia?
   1.1. What are current debates in the scientific literature? What are pros and cons?
   1.2. What are key components of palliative care early in the disease trajectory of people living with dementia?
2. What are differences between general and specialist palliative care, when provided early in the dementia disease trajectory?
3. Are there differences in the provision of palliative care early in the dementia disease trajectory, between healthcare settings?
4. What are important events that have shaped/changed the definition of palliative care and to what extent?
5. Are there differences in the provision of palliative care needs in people living with dementia early in their disease trajectory? And how are these defined and identified?
3. What are barriers and/or facilitators for initiating palliative care early in the disease trajectory? And how are these defined and identified?
4. What are potential outcomes of integration of palliative care early in the disease trajectory, for all those involved in the provision or receipt of dementia care (including their family and professional caregivers)?

**METHODS**

**Scoping review**

Scoping reviews apply systematic principles to reviewing the literature for the purposes of examining the extent, range and scope of research activity, addressing a broad review question, and including all available research, irrespective of study design.49 50 We have decided to conduct a scoping review as opposed to a systematic review given the lack of clear definition of what constitutes ‘early palliative care’ or ‘palliative care earlier in the disease trajectory’. We will perform a scoping review consistent with the methodological framework proposed by Arksey and O’Malley, refined by Levac et al.49 It will integrate qualitative and quantitative evidence through narrative juxtaposition (discussing diverse forms of evidence side by side).51 This study protocol has been constructed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scoping Reviews guidelines.52

**Databases and search strategy**

We will search the following key international databases: MEDLINE (PubMed), The Cochrane Library, CINAHL, PsycINFO, EMBASE and Web of Science (table 1). No grey literature and texts that are not peer-reviewed are

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Search string</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PubMed</strong></td>
<td><strong>Web of Science</strong></td>
</tr>
<tr>
<td><strong>EMBASE</strong></td>
<td><strong>CINAHL</strong></td>
</tr>
<tr>
<td>(“dementia”/exp OR “alzheimer disease”/exp OR “alzheimer disease”) AND (“palliative care”/exp OR “palliative care”) AND (early OR earlier OR timely) OR “early palliative care” OR “earlier palliative care” OR “timely palliative care” OR “hospice care” exp OR “hospice care” OR “terminal care”/exp OR “terminal care”) LIMITS: human, 2009-2019</td>
<td>(dementia or alzheimer or alzheimer’s) AND (“early palliative care” OR “earlier palliative care” OR “timely palliative care” OR “hospice care” OR “terminal care”) LIMITS: Academic journals, 2009-2019</td>
</tr>
<tr>
<td><strong>PsycINFO</strong></td>
<td><strong>The Cochrane Library</strong></td>
</tr>
</tbody>
</table>
| (dementia or alzheimer or alzheimer’s) AND (“early palliative care” OR “earlier palliative care” OR “timely palliative care” OR “hospice care” OR “terminal care”) LIMITS: Peer review, 2009-2019 | Dementia “early palliative care”; Dementia “earlier palliative care”; Dementia “timely palliative care”; Dementia “hospice care”; Dementia “terminal care”; Alzheimer “early palliative care”; Alzheimer “earlier palliative care”; Alzheimer “timely palliative care”; Alzheimer “hospice care”; Alzheimer “terminal care”; Alzheimer’s “early palliative care”; Alzheimer’s “earlier palliative care”; Alzheimer’s “timely palliative care”; Alzheimer’s “hospice care”; Alzheimer’s “terminal care”;
Inclusion and exclusion criteria
Criteria are outlined in table 2. We particularly include peer-reviewed research studies with different study designs, and reviews. Studies can include different palliative care domains (physical, psychological, social, spiritual) and should relate to the nature of the care provided, not the degree of training and/or experience of those providing care. We consider papers to be eligible when palliative care is provided inter-professionally, or by any type of healthcare provider (general practitioner, geriatrician, pharmacist, team, etc), and can include both generalist and specialist palliative care (providers). All settings are eligible, except for studies focusing on hospice(s) in USA and other countries with similar regulations related to a prognosis of 6 months of life or less. Papers can report on interventions (including those aimed at advance care planning, shared decision making or palliative sedation with the aim to improve quality of life), services delivery models, programmes, approaches to care or support, specific activities, tools, questionnaires. Papers with an exclusive focus on ‘advanced’, ‘end-stage’, ‘late-stage’ or ‘terminal phases/stage of’ or ‘terminal’ dementia; ‘people with dementia drawing close to death’ (having FAST (Functional Assessment Staging) score of 7c and up—routine eligibility criteria for hospice in the US; a CDR (Clinical Dementia Rating) score of more or equal to 2; or an MMSE (Mini-Mental State Examination) score of 11 or less), 55–57 are excluded on screening to ensure focus is on early stages of disease. We include all types of dementia (examples in table 2).

Study screening and selection
Studies are selected in two phases, first by title-abstract screening, then by full-text screening. In the first phase, one author (JG) will screen titles and abstracts and exclude records not fulfilling the inclusion criteria. A list of studies labelled to be included for full-text screening, is then sent to a second author (LH), as well as the list with studies of which the first author is doubting inclusion. The list of excluded studies is sent to the other authors (LVdB, JvdS and CR) who will independently screen a random sample (10% in total). In a second phase, we will obtain the full-text documents and JG will check for eligibility; which will be discussed with LH. In cases of divergences, a consensus will be reached by discussion with the other researchers (LVdB, JvdS), and if necessary, by consultation with an arbiter (CR). Study selection and screening is performed online via Rayyan QCRI. We plan to include a PRISMA flow diagram in the full review report to document the screening process, including the number of studies that were excluded and primary reason for their exclusion. 58

Quality assessment and risk of bias
We will conduct a critical appraisal of included sources of evidence and describe the methods used in each study in a table summarising the characteristics of included studies. Two authors will independently assess the quality of the studies, using the Joanna Briggs Institute Critical Appraisal Tools for use in systematic reviews. Quality assessment will be reported but studies are not excluded based on their quality score.

Data extraction and management
Included studies will be uploaded in NVivo software and data will be extracted and charted by the first author (JG). 49 We will abstract data on article characteristics and results of each study along with quotes (cf. ‘excerpts’), themes and concepts pertinent to our research questions from both results and discussion sections of the included studies. Evidence from systematic reviews and primary studies will be checked and any overlapping data will be reported to avoid over-reporting.

Narrative analysis and synthesis
We aim to apply a narrative synthesis, guided by several techniques. 57, 58 Included studies will organised into groups/clusters, a common technique in narrative synthesis 57, 58 and a useful way of aiding the process of description and analysis and looking for patterns within and across these groups. Groups are refined as the synthesis develops.

We will perform a thematic content analysis of the included studies. We will code relevant excerpts, words and text into recurring and prominent themes, via deductive coding, guided by our research questions, 59 and inductive coding. 60 Identified themes will be refined through an iterative process by JG, in close collaboration with a second author. Final themes will be reviewed and discussed by all authors to reach consensus about categories that are reported in final synthesis. Because this is an iterative process, we aim to describe the main revisions with a rationale, to increase transparency of reporting. This is the most common method adopted within scoping reviews to produce a relatively rudimentary synthesis of findings across the included studies. Separate analysis of subgroups or subsets is not planned a priori. If possible, we will report disadvantaged and minority groups separately, if sufficient data are available. We will also explore differences in different types of dementia (eg, Alzheimer’s,
Table 2  Inclusion and exclusion criteria study selection

<table>
<thead>
<tr>
<th>Inclusion criteria</th>
<th>Exclusion criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Publication date</strong></td>
<td>All connected by ‘AND’</td>
</tr>
<tr>
<td></td>
<td>Between (1 January) 2009 until date of search</td>
</tr>
</tbody>
</table>
| **Type of publication** | ► English  
► Peer-reviewed | ► Animals  
► Children  
► Adolescents (<18 years old)  
► Papers focusing solely on people living with ‘advanced’, ‘end-stage’ or ‘late-stage’ or ‘terminal phases/stage of’ or ‘terminal’ dementia; ‘people with dementia drawing close to death’ (having FAST score of 7c and up; a CDR score of more than 2 (include score of 2); an MMSE score of 11 or less).  
► Studies focusing on/including mixed populations of dementia and non-dementia (eg, cancer), when findings are not reported by disease group.  
► Studies focusing on intellectual disabilities or Down syndrome ‘AND’ dementia; neurodegenerative diseases that are not dementia (such as Parkinson’s disease and Huntington’s disease) ‘OR’ particularly occur in early adulthood (eg, adult neuronal ceroid lipofuscinoses) |
| **Population** | ► Humans  
► Adults  
► All types of dementia (all types*, defined and identified in any way) ‘OR’ adult family or professional (health, social) caregivers ‘OR’ volunteers providing/facilitating support  
► Early stages of the disease trajectory | ► Animals  
► Children  
► Adolescents (<18 years old)  
► Papers focusing solely on people living with ‘advanced’, ‘end-stage’ or ‘late-stage’ or ‘terminal phases/stage of’ or ‘terminal’ dementia; ‘people with dementia drawing close to death’ (having FAST score of 7c and up; a CDR score of more than 2 (include score of 2); an MMSE score of 11 or less).  
► Studies focusing on/including mixed populations of dementia and non-dementia (eg, cancer), when findings are not reported by disease group.  
► Studies focusing on intellectual disabilities or Down syndrome ‘AND’ dementia; neurodegenerative diseases that are not dementia (such as Parkinson’s disease and Huntington’s disease) ‘OR’ particularly occur in early adulthood (eg, adult neuronal ceroid lipofuscinoses) |
| **Subject/intervention** | ► Palliative care as defined by the WHO. Eligibility relates to the nature of the care provided, not the degree of training and/or experience of those providing care. Palliative care can be provided by any type of healthcare provider (GP, geriatrician, pharmacist, team, etc) and include both generalist and specialist palliative care (providers).  
► Interventions, services delivery models†, programmes, approaches to care or support, specific activities, tools, questionnaires that align with the aims of palliative care as defined by the WHO or one of its domains physical, psychological, social, spiritual.  
► Interventions aimed at advance care planning, ADs§ and (shared) decision-making.  
► Palliative sedation when aimed to improve quality of life.  
► Early palliative care is defined as ‘in the early stages of the disease trajectory of dementia’, starting from diagnosis | ► If the paper is explicitly referring to ‘terminal care’, or ‘palliative care during the final week/month of life’.  
► Pharmacological, medical interventions, stand-alone (palliative) therapies modifying the disease to prolong life (eg, palliative chemotherapy); specific treatments focused on relieving symptoms (eg, palliative radiotherapy, acetylcholinesterase inhibitor treatment; a cholinesterase inhibitor); specific medication or medication dosing or (de)prescribing, (dis)continuation of medication (without reference to broader framework of palliative care); nutrition (eg, specifically focusing on foregoing or stopping food and fluid, artificial hydration and nutrition, spoon feeding).  
► Post-death interventions§ focusing on grief.  
► Interventions solely focusing on music or other arts-based interventions; if not placed within the broader context of palliative care.  
► Articles focusing solely on physician-assisted dying, medical-aid-in-dying, assisted-dying, continuous sedation until death, end-of-life decision statements (focused on euthanasia); if not placed within the broader context of advance care planning.  
► Articles focusing on costs or financial burden.  
► Articles focusing on place of death or transitions in care (between healthcare settings) at the end-of-life, rather than ‘provision’ of end-of-life or palliative care. |
| **Study design** | Literature reviews and research using any methodology or method (ie, data is collected and analysed), both qualitative and quantitative are included. | No restrictions on the types of study design. |

*Inclusive in the analysis in the paper. †Interventions, services delivery models, as defined by WHO. §Advance directive.
frontotemporal dementia, Lewy bodies, prion disease, dementia with Huntington’s or young-onset dementia), if data are available. Analysis will be performed using NVivo (QSR) software. We will collate, summarise, and map the literature, informed by tabulation, to represent quantitative and qualitative data visually (including study characteristics). We will collate, summarise, and map the literature, informed by tabulation, to represent quantitative and qualitative data visually (including study characteristics).  Characteristics of included studies are reported in a separate table, describing author, year of publication, study location (country), research aim/questions, study design, study population/setting and sample size (n), methods, key findings and quality score.

We aim to develop a theoretical model of how, why and for whom early palliative care is relevant, while identifying a list of facilitators and barriers (and relationships between those) to its implementation reported. We additionally aim to report on a timeline/diagram with elements of definitions/conceptualisations of palliative care early in the disease trajectory and how those changed across time (and studies).

**Patient and public involvement**

The development of the research questions and measures were based on literature and public health efforts demonstrating that timely initiation of palliative care for persons with dementia is a priority for patients and families, and that all too often these services are unavailable or low quality. Patients and/or the public were not involved in the design, conduct, or reporting plans of this research. We aim to disseminate results through an academic publication and conferences targeting dementia care and palliative care providers.

**DISCUSSION**

In this scoping review, we will identify research regarding palliative care across various settings of dementia care, in particular related to its early initiation in the disease trajectory. A scoping review is an ideal method for the type of research questions that we propose. This is a timely study, given the anticipated increase in dementia cases across the world and the escalating associated global suffering. Research regarding palliative care has, to a large extent, focused on people with advanced dementia rather than people with less severe dementia—potentially dying from other conditions—and it is unknown how people in the earlier stages of the disease are navigating palliative care services.

We anticipate results will identify research gaps and lay out much-needed basic principles for defining and conceptualising early palliative care in dementia. It will include a theoretical model about how, for who and why palliative care can be relevant in early stages of dementia, what are facilitators and barriers, and provide insight into what is the current timeline of how this concept evolved over time and studies. Even if our scoping review cannot generate results that can guide clinicians in deciding whether palliative care in early phases might be useful, why and what it should entail, we do expect we will be able to provide insight into what is known, what are current scientific debates and what are the knowledge gaps; to ultimately bridge some of the existing controversies regarding palliative care early in the disease trajectory of people living with dementia (or to at least highlight what is currently lacking and in what areas we need further research). We do not aim to provide clarity in estimating prognosis or to develop strict criteria for when the person living with dementia should have access to palliative care.

Our scoping review protocol has some limitations. A first key issue is that in order to limit the scope of the search, we anticipate excluding literature regarding care delivery similar to the US hospice system and therefore studies looking at the last 6 months of life; even if the population does not necessarily have advanced dementia. Given however that many people die without reaching the stages of advanced dementia, we might have excluded a...
A particular group of people who have dementia and are in hospices or receive palliative care but are not necessarily identified as having advanced dementia. Second, because there is a lack of a clear definition of what ‘early palliative care’ entails, the aim of this paper is focused on palliative care ‘early in the disease trajectory’ of people living with dementia. Third, given we have made a trade-off between the specificity of using dementia as a search term versus cognitive impairment, which includes many other problems besides dementia, we decided not to include cognitive impairment or dementia types other than ‘Alzheimer’s’ in our search strategy. Applying a specific search string (ruling out non-diagnosed dementia) might lead to missing some relevant articles. When we report on results, we will highlight whether these are applicable to dementia or MCI (or distinct types of dementia), given that it is not sure whether each cognitive impairment will progress in dementia, hence people with cognitive impairment might not be needing the same information on prognosis, anticipating symptoms, challenges, etc. Fourth, our search strategy is searching for general palliative care and might therefore not be sensitive to specific interventions that are considered to be part of palliative care (e.g., we may miss papers focusing on advance care planning, as this was not explicitly included in our search). Any deviations from the scope of the review protocol outlined here, shall be noted in our final paper, along with a rationale and a reflection on the potential effect on the results.

ETHICS AND DISSEMINATION
A scoping review of published review articles is a novel approach for examining the breadth of literature. It does not require ethics approval. Although this is our first step in establishing a foundation for a research agenda, we will be disseminating results through a publication and conferences targeting dementia care and palliative care providers.

Start date

Anticipated completion date
End of September 2021.

Author affiliations
1 Atlantic Fellow for Equity in Brain Health, Global Brain Health Institute (GBHI), University of California, San Francisco, California, USA
2 End-of-Life Care Research Group, Department of Family Medicine & Chronic Care, Vrije Universiteit Brussel (VUB), Brussels, Belgium
3 Department of Family Medicine and Chronic Care, Vrije Universiteit Brussel (VUB), Brussels, Belgium
4 Division of Palliative Care and Geriatric Medicine and the Mongan Institute for Aging and Serious Illness, Massachusetts General Hospital, Boston, Massachusetts, USA
5 Department of Physiological Nursing, University of California San Francisco, San Francisco, California, USA
6 Department of Primary and Community Care, Radboud University Nijmegen, Nijmegen, Gelderland, Netherlands
7 Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
8 UCSF Library, University of California, San Francisco, California, USA
9 Center for Palliative Care, Harvard Medical School, Boston, Massachusetts, USA

Twitter Joni Gilissen @JoniGilissen

Acknowledgements
The authors want to thank the UCSF librarians for their support, and the language editor for English language editing.

Contributors
JG conceived of and developed the protocol, which was reviewed by all authors. PT and JG conceived of the search strategy, PT executed the search. JG, LH, JvdS, LvdB and CR contributed to the development of the inclusion and exclusion criteria. The final manuscript was drafted by JG and approved by LH, JvdS, LvdB, PT and CR.

Funding
JG is a Senior Atlantic Fellow at the Atlantic Fellows for Equity in Brain Health Programme (Atlantic Philanthropies), Global Brain Health Institute (GBHI), University of California San Francisco (no grant number) and Maurange Fund Laureate, King Baudouin Foundation, Belgium (no grant number).

Competing interests
None declared.

Patient and public involvement
Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

Patient consent for publication
Not required.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD
Joni Gilissen http://orcid.org/0000-0002-5388-495X

REFERENCES
7 World Health Organization. Strengthening of palliative care as a component of integrated treatment throughout the life course 2014.

7 Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
8 UCSF Library, University of California, San Francisco, California, USA
9 Center for Palliative Care, Harvard Medical School, Boston, Massachusetts, USA


Nakanishi M, van der Steen JT. National dementia plans to address escalating global palliative care needs. Palliat Med 2020;34:968-967.


